Genentech

Survey ranks top biotech, biopharma employers

Fiercebiotech (Free subscription) | 10/10/2008

Science announced the results of its annual Top Employers survey. After placing second last year, Genentech once again claimed the top spot for the sixth year. Missouri-based Monsanto climbed six spots to come in at number two this year, with Genzyme rounding out the top three. The annual web-based survey, now in its seventh year, polls employees of biotech, biopharma and pharmaceutical companies,...

• Monsanto Recognized as Top Biotechnology Employer by Science Magazine - PR News Wire

Winners & Losers: Wells Fargo Shares Get a Boost; RIMM Pops on New Smartphone Announcement; Genentech Shares Drop on Investor Concerns

World of stocks (Free subscription) | 10/09/2008

TheStreet.com Winners & Losers Financial Winners & Losers: Wells Tech Winners & Losers: RIMM 10/8/2008 4:32 PM EDT Health Winners & Losers: Genentech 10/8/2008 3:27 PM EDT TSC Ratings' Upgrades: America Movil 10/8/2008 3:45 PM EDT More News from TheStreet.com ETFs Small Business Investing A-Z Life and Money Moneymaking Strategies Stocks Sink Despite Global Rate Cuts | Article U.S. stocks swung wildly...

Genentech Has Mixed Results In Cancer Fight

Forbes (Free subscription) | 10/08/2008

Genentech-Biogen rheumatoid arthritis drug slows progression of lymphocytic leukemia, but trial of lung cancer treatment fails.

Good News For Rituxan

Forbes (Free subscription) | 10/07/2008

Genentech and Biogen's rheumatoid arthritis drug slows the progression of lymphocytic leukemia, studies show.

Genentech touts test of Rituxan plus chemo vs. leukemia

The Sacramento Business Journal (Free subscription) | 10/07/2008

Biotech giant Genentech Inc. and partner Biogen Idec said a combined treatment of Rituxan and chemotherapy did well in patients with chronic lymphocytic leukemia, the most common adult leukemia. (DNA)

Genentech touts test of Rituxan plus chemo vs. leukemia

The East Bay Business Times (Free subscription) | 10/07/2008

Biotech giant Genentech Inc. and partner Biogen Idec said a combined treatment of Rituxan and chemotherapy did well in patients with chronic lymphocytic leukemia, the most common adult leukemia. (BIIB) (DNA) (OSIP)

Genentech touts test of Rituxan plus chemo vs. leukemia

The San Francisco Business Times (Free subscription) | 10/07/2008

Biotech giant Genentech Inc. and its partner, Biogen Idec, said a combined treatment of Rituxan and chemotherapy did well in patients with chronic lymphocytic leukemia, the most common adult leukemia. (BIIB) (DNA) (OSIP)

Genentech And Biogen Score Against Leukemia

Forbes (Free subscription) | 10/07/2008

Companies' arthritis drug helps patients with stubborn strains of blood cancer.

Rituxan Study Meets Endpoint

Contract Pharma Breaking News (Free subscription) | 10/07/2008

Genentech and Biogen Idec's Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL), compared to chemotherapy alone. There were no new or unexpected safety signals reported in the...

Phase III Study Showed Rituxan Combined With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Lymphocytic Leukemia

Medical News Today (Free subscription) | 10/07/2008

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced that a global Phase III study of Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone....

Study: Genentech-Avastin Combination Does Not Boost Lung Cancer Survival

VitaBeat (Free subscription) | 10/07/2008

A large-scale clinical trial combining two popular lung cancer drugs Tarceva and Avastin has showed no increase in survival rates. However, the combination treatment kept the disease from progressing for a longer period than Tarceva alone, the study found. Tarceva is marketed by Genentech and Avastin by Roche. Roche Holding AG sells both drugs in Europe.

• Two Drugs Don't Boost Lung Cancer Survival: Roche - Health - The Post Chronicle
• Two drugs don't boost lung cancer survival: Roche - Reuters UK

Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival..

EuroInvestor.co.uk (Free subscription) | 10/07/2008

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that a global Phase III study of Rituxan ® (rituximab) in combination with fludarabine.. - Read more

Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

Business Wire (Free subscription) | 10/07/2008

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that a global Phase III study of Rituxan

Genentech Shares Drop on Drug Test

Red Orbit (Free subscription) | 10/07/2008

By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer.

• Genentech, Osi Lung Cancer Study Falls Short - The Street
• Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Com.. - EuroInvestor.co.uk
• See the 4 articles on the same subject

Genentech Set Back by Drug Study

Law Blog - WSJ.com (Free subscription) | 10/07/2008

Genentech Inc. and OSI Pharmaceuticals Inc. said a late-stage trial showed that adding the cancer medicine Avastin to the drug Tarceva didn't prolong the lives of patients with advanced lung cancer.